RESUNET (GETNE-2016-01): A phase II study to evaluate the efficacy and safety of the rechallenge with sunitinib in G1/G2 pancreatic neuroendocrine tumours (pNET). A Spanish Task Force Group in neuroendocrine and endocrine tumours (GETNE) study

Grande, E.Espinosa-Olarte, P.Serrano, R.Jimenez, P.Alonso, T.Benavent, M.Capdevila Castillon, J.Lacasta, A.Yaya Tur, R.Carmona, A.Gallegos, I.Rodriguez, R. M.Castillo Trujillo, A. O.Molina Cerrillo, J.Hernando, J.Bujedo Martinez, A.Garcia-Carbonero, R.2025-01-072025-01-072020-09-010923-7534https://hdl.handle.net/10668/25711enRESUNET (GETNE-2016-01): A phase II study to evaluate the efficacy and safety of the rechallenge with sunitinib in G1/G2 pancreatic neuroendocrine tumours (pNET). A Spanish Task Force Group in neuroendocrine and endocrine tumours (GETNE) studyconference outputopen access10.1016/j.annonc.2020.08.13871569-8041http://www.annalsofoncology.org/article/S0923753420413833/pdf573469101461